Author

B. Salome

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. M. Farkas· 2 shared B. Lee· 2 shared D. Geanon· 2 shared E. Hegewisch-Solloa· 2 shared E. M. Mace· 2 shared G. Kelly· 2 shared J. Daza· 2 shared J. P. Sfakianos· 2 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. M. Farkas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Elevated HLA-E and NKG2A as a consequence of chronic immune activation defines resistance to M. bovis BCG immunotherapy in Non-Muscle-Invasive Bladder Cancer

D. Ranti, Y.-S. Wang, J. Daza, C. Bieber, B. Salome, E. Merritt, J.-A. Cavallo, E. Hegewisch-Solloa, E. M. Mace, A. M. Farkas, S. Schroff, B. Lee, M. Tran, T. Strandgaard, S. V. Lindskrog, , A. Horowitz

The paper identifies elevated HLA-E and NKG2A as markers of resistance to BCG immunotherapy in NMIBC, linked to immune escape mechanisms.

bioRxiv · Mar 6, 2022 · PreprintImmunology

NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer

B. Salome, J. P. Sfakianos, J. Daza, A. Charap, C. Hammer, R. Banchereau, A. M. Farkas, D. Geanon, G. Kelly, R. M. de Real, B. Lee, K. G. Beaumont, S. Shroff, Y. S. A. Wang, Y.-C. Wang, , Mariath

This study identifies NKG2A and HLA-E as an alternative immune checkpoint axis in bladder cancer, showing NKG2A+ CD8 T cells can bypass HLA-ABC loss through TCR-independent cytotoxicity.

bioRxiv · Mar 4, 2022 · PreprintImmunology